research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data
Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
research Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
research 13C-NMR study of 4-azasteroids in solution and solid state
4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.
research The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental events.
The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
research L-(+)-Tartaric Acid Minimally Affects the Viability or Molecular Signature but Increase the Expression of Selected Hair Growth Associated Genes in Human Dermal Papilla Cells
L-(+)-Tartaric Acid may help increase certain hair growth genes without harming cells.
research 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (vol 35, pg e243, 2021)
Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology
Acitretin is effective for severe skin conditions but has significant side effects and requires careful monitoring.